

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

CD154-VioBlue, human

RRID:AB_2660188

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-098-885, RRID:AB_2660188

Antibody Information

URL: http://antibodyregistry.org/AB_2660188

Proper Citation: Miltenyi Biotec Cat# 130-098-885, RRID:AB_2660188

Target Antigen: CD154

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 1-2019; Target Distribution basophils, dendritic cells, lymphocytes, macrophages, mast cells, monocytes, NK cells, T cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-114-135. (RRID:AB_2751210).

Antibody Name: CD154-VioBlue, human

Description: This monoclonal targets CD154

Target Organism: non-human primate, human

Clone ID: 5C8

Antibody ID: AB_2660188

Vendor: Miltenyi Biotec

Catalog Number: 130-098-885

Record Creation Time: 20250820T060416+0000

Record Last Update: 20250820T231352+0000

Ratings and Alerts

No rating or validation information has been found for CD154-VioBlue, human.

Warning: Discontinued: 2021

Discontinued: 1-2019; Target Distribution basophils, dendritic cells, lymphocytes, macrophages, mast cells, monocytes, NK cells, T cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-114-135. (RRID:AB_2751210).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ben-Shalom N, et al. (2026) Decoy antibodies block extracellular HSP70, prevent self-signaling, and inhibit melanoma cell survival. Cell reports, 45(5), 117300.